Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Phase 2
Active, not recruiting
- Conditions
- Newly Diagnosed Glioblastoma
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- MimiVax, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT05163080
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Norton Cancer Center, Louisville, Kentucky, United States
News
No news found